| 764028 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
142 Enhanced antitumoral activity of HER2-CAR-Ts in comparison to trastuzumab in a live cell imaging supported 3D assay |
2021-11-01 |
10.1136/jitc-2021-sitc2021.142 |
Schaich Katharina, Moiset Gemma, Vermond Sophie, Hazenoot Monique, Lashuk Kanstantsin, Oswald Eva, Holt Sanne, Schuler Julia |
| 764027 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
862 Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.862 |
Kenkel Justin, Ho Po, Kongara Sameera, Henning Karla, Kreder Cindy, Nolin Jess, Chapin Steven, Kowanetz Marcin, Alonso Michael, Ackerman Shelley, Engleman Edgar, Dornan David |
| 764026 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
861 Reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.861 |
Keller Peter, Mazo Irina, Gao Yun, Reddy Vijayapal, Caballero Francisco, Kazer Sam, Fu Amina, Sun Yi, Miller Dannah, Gianani Roberto, Marvin James, Stephens Bret, Beatty Gregory, Jenkins Russell, Andrian Ulrich Von, Krappmann Daniel, Mempel Thorsten |
| 764025 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
857 Selective Treg depletion in solid tumors with ALD2510, a novel humanized CD25-specific, IL-2 sparing monoclonal antibody |
2021-11-01 |
10.1136/jitc-2021-sitc2021.857 |
Houacine Jemila, Marie-Cardine Anne, Roy Aude Le, Giustiniani Jérôme, Abes Riad, Chrétien Anne-Sophie, Fattori Stéphane, Gorvel Laurent, Bensussan Armand, Olive Daniel, Foussat Arnaud |
| 764024 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models |
2021-11-01 |
10.1136/jitc-2021-sitc2021.854 |
Gray Elizabeth, Epp Angela, Ulrich Michelle, Sahetya Disha, Hensley Kelly, Hahn Julie, Allred Sean, Haass Jane, Snead Katie, Lucas Sasha, Gosink John, Boyce Rogely, Trueblood Esther, Treuting Piper, Frantz Chris, Smith Alyson, Schrum Jason, Nazarenko Natalya, Gardai Shyra |
| 764023 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
853 ACTM-838: a microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs after IV dosing in T-cell excluded solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.853 |
Kehoe Haixing, Iannello Alexandre, Cheung Keith, Peterson Bret, Marotel Marie, Tribble Sara, He Hailey, Hodgins Jonathan, Ardolino Michele, Rae Christopher, Thanos Christopher, Glickman Laura |
| 764022 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
851 Harnessing innate immunity in cancer therapies: the example of natural killer cell engagers |
2021-11-01 |
10.1136/jitc-2021-sitc2021.851 |
Demaria Olivier, Vivier Eric, Vetizou Marie, Alvarez Audrey Blanchard, Habif Guillaume, Bonnafous Cécile, Bokobza Sivan, Represa Agnès, Rossi Benjamin, Batista Luciana, Vagne Constance, Carpentier Sabrina, Cornen Stéphanie, Morel Ariane, Perrot Ivan, Morel Yannis, Gauthier Laurent |
| 764021 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
849 ReSTORE T cell engager platform depletes MDSC in parallel with antigen-specific solid tumor cytotoxicity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.849 |
Eckard Sterling, Rojo Bianca, Mei Li, Ponce Alberto, Chun Patrick, Smith Victoria |
| 764020 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
846 Pre-clinical validation of a FLT3L-fusion protein for dendritic cell expansion and anti-tumor efficacy |
2021-11-01 |
10.1136/jitc-2021-sitc2021.846 |
Kuhne Michelle, Chu Hamlet, Ng Sarah, Clarke Christopher, Carr Brian, Baca Manuel, Hung Magdeleine, Nagel Mark, Ambrogelly Alexandre, Wilson Nicholas |
| 764019 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
671 Biological impacts of standard of care chemotherapies on immune effector cells from AML patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.671 |
Zhigarev Dmitry, MacFarlane Alexander, Drenberg Christina, Nejati Reza, Varshavsky Asya, Campbell Kerry |
